1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies

BACKGROUND: Current oral therapeutic options for chronic mucocutaneous candidiasis (CMC) are often associated with resistance and toxicity. Amphotericin B (AMB) has broad fungicidal activity and markedly resists emergence of resistance but requires parenteral administration and monitoring for signif...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Kibathi, Lilian, Kumar, Parag, Lionakis, Michail, Urban, Amanda, Ferre, Elise, McManus, Maryellen, Colton, Benjamin, Lambros, Chris, Lu, Ruying, Mannino, Raphael, Tramont, Edmund, Freeman, Alexandra F
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253191/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1244
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires